Who are Cyclophosphamide + Bortezomib + Dexamethasone regimen's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cyclophosphamide-bortezomib-dexamethasone-regimen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Cyclophosphamide + Bortezomib + Dexamethasone regimen — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cyclophosphamide + Bortezomib + Dexamethasone regimen (Cyclophosphamide + Bortezomib + Dexamethasone regimen) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy regimen (alkylating agent + proteasome inhibitor + corticosteroid). Area: Oncolo

phase 3 Combination chemotherapy regimen (alkylating agent + proteasome inhibitor + corticosteroid) DNA (cyclophosphamide); 26S proteasome (bortezomib); glucocorticoid receptor (dexamethasone) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Cyclophosphamide + Bortezomib + Dexamethasone regimen (Cyclophosphamide + Bortezomib + Dexamethasone regimen) — Assistance Publique - Hôpitaux de Paris. This three-drug combination kills cancer cells through DNA damage (cyclophosphamide), proteasome inhibition (bortezomib), and glucocorticoid immunosuppression (dexamethasone).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cyclophosphamide + Bortezomib + Dexamethasone regimen TARGET	Cyclophosphamide + Bortezomib + Dexamethasone regimen	Assistance Publique - Hôpitaux de Paris	phase 3	Combination chemotherapy regimen (alkylating agent + proteasome inhibitor + corticosteroid)	DNA (cyclophosphamide); 26S proteasome (bortezomib); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy regimen (alkylating agent + proteasome inhibitor + corticosteroid) class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cyclophosphamide + Bortezomib + Dexamethasone regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/cyclophosphamide-bortezomib-dexamethasone-regimen. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab